FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947527100> ?p ?o ?g. }

• W2947527100 abstract "e12032 Background: The study objective was to estimate the long-term consequences of recurrences following treatment with trastuzumab (TRA) among women with HER2+ early stage breast cancer (BC) in the United States (US). Methods: A simulation model was constructed to estimate the following outcomes for each combination of hormone receptor (+/-) and nodal (+/-) status: number of recurrences, direct medical cost and indirect cost attributed to recurrences. The number of women aged ≥18 years with newly diagnosed HER2+ BC between 2018 and 2037 was estimated using SEER incidence rates (assumed constant over time) and from US Census data and accounted for the proportion of women utilizing adjuvant TRA by nodal status and age (assumed constant over time). The recurrence rate to any regional, distant or contralateral site was based on the long-term follow-up of the HERceptin Adjuvant (HERA) trial (expected 20-year recurrence proportions of 27.6% for TRA and 36.7% without TRA). Medical and pharmacy costs due to a recurrence were based on a 3-year study of metastatic BC patients treated with HER2 targeted agents. Beyond year 3, cost increased by 4.5% per year. The indirect costs of recurrences included loss of income from early retirement valued at the mean hourly wage, work absenteeism ($6,960/year), and reduced productivity while at work ($3,456/year). Non-cancer related mortality was estimated using SEER data. Results: We estimated that there would be 411,373 incident cases of early stage BC who would receive adjuvant TRA treatment from 2018 to 2037. Following each annual cohort for 20 years, we estimated that there would be 112,700 recurrences after TRA treatment and 149,674 recurrences without TRA treatment. The 20-year direct medical costs of recurrences were estimated to be $28.2 and $37.5 billion with and without TRA, respectively and the indirect costs were estimated to be $4.1 and $5.6 billion with and without TRA, respectively. Conclusions: Although TRA reduced recurrences by 25% in our 20-year model, there was a substantial number of recurrences. Future research will assess the clinical and economic impact of newer HER2 directed therapies in the adjuvant (pertuzumab, T-DM1) and extended adjuvant (neratinib) setting." @default.
• W2947527100 created "2019-06-07" @default.
• W2947527100 creator A5017550097 @default.
• W2947527100 creator A5018773741 @default.
• W2947527100 creator A5024474312 @default.
• W2947527100 creator A5068367016 @default.
• W2947527100 creator A5072015843 @default.
• W2947527100 creator A5085464902 @default.
• W2947527100 creator A5086242530 @default.
• W2947527100 date "2019-05-20" @default.
• W2947527100 modified "2023-09-23" @default.
• W2947527100 title "Modeling the consequences of recurrences after trastuzumab treatment of HER2+ early-stage breast cancer." @default.
• W2947527100 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.e12032" @default.
• W2947527100 hasPublicationYear "2019" @default.
• W2947527100 type Work @default.
• W2947527100 sameAs 2947527100 @default.
• W2947527100 citedByCount "0" @default.
• W2947527100 crossrefType "journal-article" @default.
• W2947527100 hasAuthorship W2947527100A5017550097 @default.
• W2947527100 hasAuthorship W2947527100A5018773741 @default.
• W2947527100 hasAuthorship W2947527100A5024474312 @default.
• W2947527100 hasAuthorship W2947527100A5068367016 @default.
• W2947527100 hasAuthorship W2947527100A5072015843 @default.
• W2947527100 hasAuthorship W2947527100A5085464902 @default.
• W2947527100 hasAuthorship W2947527100A5086242530 @default.
• W2947527100 hasConcept C121608353 @default.
• W2947527100 hasConcept C126322002 @default.
• W2947527100 hasConcept C143998085 @default.
• W2947527100 hasConcept C146357865 @default.
• W2947527100 hasConcept C151730666 @default.
• W2947527100 hasConcept C2779786085 @default.
• W2947527100 hasConcept C530470458 @default.
• W2947527100 hasConcept C71924100 @default.
• W2947527100 hasConcept C86803240 @default.
• W2947527100 hasConceptScore W2947527100C121608353 @default.
• W2947527100 hasConceptScore W2947527100C126322002 @default.
• W2947527100 hasConceptScore W2947527100C143998085 @default.
• W2947527100 hasConceptScore W2947527100C146357865 @default.
• W2947527100 hasConceptScore W2947527100C151730666 @default.
• W2947527100 hasConceptScore W2947527100C2779786085 @default.
• W2947527100 hasConceptScore W2947527100C530470458 @default.
• W2947527100 hasConceptScore W2947527100C71924100 @default.
• W2947527100 hasConceptScore W2947527100C86803240 @default.
• W2947527100 hasLocation W29475271001 @default.
• W2947527100 hasOpenAccess W2947527100 @default.
• W2947527100 hasPrimaryLocation W29475271001 @default.
• W2947527100 hasRelatedWork W1969411909 @default.
• W2947527100 hasRelatedWork W1983181224 @default.
• W2947527100 hasRelatedWork W2036233356 @default.
• W2947527100 hasRelatedWork W2053485143 @default.
• W2947527100 hasRelatedWork W2089495169 @default.
• W2947527100 hasRelatedWork W2136704455 @default.
• W2947527100 hasRelatedWork W2415260596 @default.
• W2947527100 hasRelatedWork W2589975159 @default.
• W2947527100 hasRelatedWork W2597884902 @default.
• W2947527100 hasRelatedWork W2751941543 @default.
• W2947527100 hasRelatedWork W2794556119 @default.
• W2947527100 hasRelatedWork W2930898102 @default.
• W2947527100 hasRelatedWork W2936228289 @default.
• W2947527100 hasRelatedWork W2937006364 @default.
• W2947527100 hasRelatedWork W2942507498 @default.
• W2947527100 hasRelatedWork W2944347740 @default.
• W2947527100 hasRelatedWork W2955876311 @default.
• W2947527100 hasRelatedWork W3030971054 @default.
• W2947527100 hasRelatedWork W3045777911 @default.
• W2947527100 hasRelatedWork W3139325184 @default.
• W2947527100 isParatext "false" @default.
• W2947527100 isRetracted "false" @default.
• W2947527100 magId "2947527100" @default.
• W2947527100 workType "article" @default.